Patient
P2B-139
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Sarcoma Oncology Center (Santa Monica, CA) (Dr. Reyes)
consented 2013-07-24
Adverse events
4
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 4
Grade 2 decreased appetite with onset in cycle 5 (2013-11-10); assessed as not related to study drug (not related); resolved 2013-11-23.
Grade 1 nausea with onset in cycle 3 (2013-09-20); assessed as not related to study drug (not related); resolved 2013-09-23.
Grade 3 aspartate aminotransferase increased with onset in cycle 2 (2013-09-14); assessed as not related to study drug (unlikely); resolved 2013-09-27; action: drug interrupted.
Grade 2 alopecia with onset in cycle 1 (2013-08-20); assessed as related to study drug (probable); not resolved at last follow-up.
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.